These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2552661)

  • 21. Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.
    Han X; Zou J; Wang X; Guo W; Huo G; Shen R; Xiang W
    Viral Immunol; 2010 Oct; 23(5):531-9. PubMed ID: 20883167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse.
    Zheng YH; Nakaya T; Sentsui H; Kameoka M; Kishi M; Hagiwara K; Takahashi H; Kono Y; Ikuta K
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():807-20. PubMed ID: 9129653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.
    Mealey RH; Leib SR; Pownder SL; McGuire TC
    J Virol; 2004 Sep; 78(17):9295-305. PubMed ID: 15308724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus.
    Montelaro RC; Robey WG; West MD; Issel CJ; Fischinger PJ
    J Gen Virol; 1988 Jul; 69 ( Pt 7)():1711-7. PubMed ID: 2839603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epitope analysis of glycoprotein I of pseudorabies virus.
    Jacobs L; Meloen RH; Gielkens AL; Van Oirschot JT
    J Gen Virol; 1990 Apr; 71 ( Pt 4)():881-7. PubMed ID: 1691269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.
    Leroux C; Craigo JK; Issel CJ; Montelaro RC
    J Virol; 2001 May; 75(10):4570-83. PubMed ID: 11312327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigenic reactivity of the major glycoprotein of equine infectious anemia virus, a retrovirus.
    Montelaro RC; West M; Issel CJ
    Virology; 1984 Jul; 136(2):368-74. PubMed ID: 6205503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.
    Cook RF; Berger SL; Rushlow KE; McManus JM; Cook SJ; Harrold S; Raabe ML; Montelaro RC; Issel CJ
    J Virol; 1995 Mar; 69(3):1493-9. PubMed ID: 7853482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.
    Craigo JK; Leroux C; Howe L; Steckbeck JD; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2002 Jun; 83(Pt 6):1353-1359. PubMed ID: 12029150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of variable regions in the envelope and S3 open reading frame of equine infectious anemia virus.
    Alexandersen S; Carpenter S
    J Virol; 1991 Aug; 65(8):4255-62. PubMed ID: 1649329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV).
    Zhou W; Cook RF; Cook SJ; Hammond SA; Rushlow K; Ghabrial NN; Berger SL; Montelaro RC; Issel CJ
    Vet Microbiol; 2002 Aug; 88(2):127-51. PubMed ID: 12135633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.
    Wang X; Wang S; Lin Y; Jiang C; Ma J; Zhao L; Lv X; Wang F; Shen R; Zhou J
    Virus Genes; 2011 Apr; 42(2):220-8. PubMed ID: 21369830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.
    Leroux C; Issel CJ; Montelaro RC
    J Virol; 1997 Dec; 71(12):9627-39. PubMed ID: 9371627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.
    Ma J; Jiang C; Lin Y; Wang X; Zhao L; Xiang W; Shao Y; Shen R; Kong X; Zhou J
    Arch Virol; 2009; 154(5):867-73. PubMed ID: 19363668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus.
    Rushlow K; Olsen K; Stiegler G; Payne SL; Montelaro RC; Issel CJ
    Virology; 1986 Dec; 155(2):309-21. PubMed ID: 2431539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.
    Liu C; Cook SJ; Craigo JK; Cook FR; Issel CJ; Montelaro RC; Horohov DW
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):161-9. PubMed ID: 25176006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and validation of an ELISA for equine infectious anemia (EIA) diagnosis using synthetic peptides.
    Soutullo A; Verwimp V; Riveros M; Pauli R; Tonarelli G
    Vet Microbiol; 2001 Mar; 79(2):111-21. PubMed ID: 11230933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies and PMBC from EIAV infected carrier horses recognize gp45 and p26 synthetic peptides.
    Soutullo A; García MI; Bailat A; Racca A; Tonarelli G; Malan Borel I
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):335-43. PubMed ID: 16105689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.
    Lonning SM; Zhang W; Leib SR; McGuire TC
    J Virol; 1999 Apr; 73(4):2762-9. PubMed ID: 10074123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.
    Megret F; Hugnot JP; Falconar A; Gentry MK; Morens DM; Murray JM; Schlesinger JJ; Wright PJ; Young P; Van Regenmortel MH
    Virology; 1992 Apr; 187(2):480-91. PubMed ID: 1372140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.